Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

NLS-3 (Levophacetoperane or (R,R) Phacetoperane): A Reverse Ester of Methylphenidate: A Literature Review

Author(s): Eric Konofal*, Michel Lecendreux, Jean-Charles Bizot, Anh-Tuan Lormier and Bruno Figadère*

Volume 31, Issue 9, 2024

Published on: 31 March, 2023

Page: [1069 - 1081] Pages: 13

DOI: 10.2174/0929867330666230120161837

Price: $65

Abstract

Background: NLS-3 or (R, R) enantiomer of phacetoperane (levophacetoperane) is the reverse ester of methylphenidate, a well-documented psychostimulant marketed for the treatment of attention-deficit/hyperactivity disorder (ADHD) since the end of 1950s. Launched in Canada and Europe by Specia Rhône-Poulenc and Rhodia, marketed as Lidepran® (8228 R.P.), for the treatment of obesity and depression, phacetoperane became an increasingly popular psychiatric medication from 1959 to 1967. Previous data supported that the stimulant effect of phacetoperane differed from those of other medications acting on the catecholamine system (e.g., methylphenidate, amphetamine), with an advantage of benefit/risk balance. Method: The goal of this study is to characterize the binding profile of NLS-3 using in vitro and in vivo assays and hypothesize potential therapeutic uses considering all available data. Results: A complete binding profile assay confirmed the potential benefit of phacetoperane with a higher benefit/risk compared to other stimulants. NLS-3 synthesis resulted from phenylketone, which is also used for the synthesis of methylphenidate. It differs from that used by Rhône-Poulenc SA laboratories, allowing the possibility of individualizing several enantiomers not synthesized previously. The present review also confirmed extensive clinical use of the compound in almost one thousand children and adolescents in large dose ranges with fewer side effects versus comparative treatments. Furthermore, levophacetoperane was found to be generally well-tolerated by the subjects. Conclusion: NLS-3 could be a safer and more potent alternative to stimulants for patients with ADHD.

« Previous Next »
[1]
Bradley, C. The behavior of children receiving benzedrine. Am. J. Psychiatry, 1937, 94(3), 577-585.
[http://dx.doi.org/10.1176/ajp.94.3.577]
[2]
Cortese, S.; Adamo, N.; Del Giovane, C.; Mohr-Jensen, C.; Hayes, A.J.; Carucci, S.; Atkinson, L.Z.; Tessari, L.; Banaschewski, T.; Coghill, D.; Hollis, C.; Simonoff, E.; Zuddas, A.; Barbui, C.; Purgato, M.; Steinhausen, H.C.; Shokraneh, F.; Xia, J.; Cipriani, A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry, 2018, 5(9), 727-738.
[http://dx.doi.org/10.1016/S2215-0366(18)30269-4] [PMID: 30097390]
[3]
Wigal, T.L.; Newcorn, J.H.; Handal, N.; Wigal, S.B.; Mulligan, I.; Schmith, V.; Konofal, E. a double-blind, placebo- controlled, phase ii study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). CNS Drugs, 2018, 32(3), 289-301.
[http://dx.doi.org/10.1007/s40263-018-0503-y] [PMID: 29557078]
[4]
Nageye, F.; Cortese, S. Beyond stimulants: A systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev. Neurother., 2019, 19(7), 707-717.
[http://dx.doi.org/10.1080/14737175.2019.1628640] [PMID: 31167583]
[5]
Polanczyk, G.; de Lima, M.S.; Horta, B.L.; Biederman, J.; Rohde, L.A. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry, 2007, 164(6), 942-948.
[http://dx.doi.org/10.1176/ajp.2007.164.6.942] [PMID: 17541055]
[6]
Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet, 2020, 395(10222), 450-462.
[http://dx.doi.org/10.1016/S0140-6736(19)33004-1] [PMID: 31982036]
[7]
Thorpy, M.J.; Hiller, G. The medical and economic burden of narcolepsy: Implications for managed care. Am. Health Drug Benefits, 2017, 10(5), 233-241.
[PMID: 28975007]
[8]
Konofal, É.; Dolitsky, D. ADHD andits medications, an illustrated history over time. Impulsion naturelle, 2019. Available from: http://impulsion-naturelle.fr/produit/ adhd-its-medications-an-illustrated-history-over/
[9]
Morton, W.A.; Stock, G.G. methylphenidate abuse and psychiatric side effects. Prim. Care Companion J. Clin. Psychiatry, 2000, 2(5), 159-164.
[http://dx.doi.org/10.4088/PCC.v02n0502] [PMID: 15014637]
[10]
Conners, C.K.; Eisenberg, L. The effects of methylphenidate on symptomatology and learning in disturbed children. Am. J. Psychiatry, 1963, 120(5), 458-464.
[http://dx.doi.org/10.1176/ajp.120.5.458] [PMID: 14051237]
[11]
Cortese, S.; Holtmann, M.; Banaschewski, T.; Buitelaar, J.; Coghill, D.; Danckaerts, M.; Dittmann, R.W.; Graham, J.; Taylor, E.; Sergeant, J. Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J. Child Psychol. Psychiatry, 2013, 54(3), 227-246.
[http://dx.doi.org/10.1111/jcpp.12036] [PMID: 23294014]
[12]
Sivadon, P. Chanoit; Azoulay. First clinical results of the use of a new psycho-tonic. The 8228 R.P. Ann. Med. Psychol. (Paris), 1959, II, 536-537.
[PMID: 13854835]
[13]
Konofal, E.; Figadere, B. Phacetoperane to treat attention deficit hyperactivity disorder. EP Patents EP2785344B1, 2016.
[14]
Thai, D.L.; Sapko, M.T.; Reiter, C.T.; Bierer, D.E.; Perel, J.M. Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives. J. Med. Chem., 1998, 41(4), 591-601.
[http://dx.doi.org/10.1021/jm970620j] [PMID: 9484508]
[15]
Nahm, S.; Weinreb, S.M. N-methoxy-n-methylamides as effective acylating agents. Tetrahedron Lett., 1981, 22(39), 3815-3818.
[http://dx.doi.org/10.1016/S0040-4039(01)91316-4]
[16]
Dargazanli, G.; Estienne-Bouhtou, G.; Marabout, B.; Roger, P.; Sevrin, M. N-phenyl(piperidin-2-Yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy. EP Patent EP1527048A2, 2005.
[17]
Dewar, G.H.; Parfitt, R.T.; Sheh, L. Stereochemical features of reduction and elimination reactions of 8-emthyl-6-phenyl-8-azabicyclo(3.2.1)oct-6-ene (6-phenyl-6-tropene). Chem. Informationsd., 1985, 1, 16.
[18]
Pham, V.C.; Charlton, J.L. Methyl (S)-Lactate as a chiral auxiliary in the asymmetric synthesis of Bao Gong Teng A. J. Org. Chem., 1995, 60(24), 8051-8055.
[http://dx.doi.org/10.1021/jo00129a053]
[19]
Laboratoires specia. Lidepran: Psychoactive lidepran; Paris, 1963.
[20]
Ziolko, H.U. The significance of psychodynamic factors for the effect of phenylpiperidylcarbinol (Bayer 1313). Med. Exp. Int. J. Exp. Med., 1960, 2, 224-227.
[PMID: 13847609]
[21]
Michel, J.R.; Marie, J.N. New esters. US Patent US2928835A, 1960.
[22]
Ramirez, A.; Vial, H.; Barailler, J.; Pacheco, H. Effects of levophacetoperane, pemoline, fenozolone, and centrophenoxine on catecholamines and serotonin uptake in various parts of the rat brain. C.R. Acad. Hebd. Seances Acad. Sci. D, 1978, 187(1), 53-56.
[PMID: 29714]
[23]
Snyder, S.H.; Coyle, J.T. Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J. Pharmacol. Exp. Ther., 1969, 165(1), 78-86.
[PMID: 5782836]
[24]
Hanna, C.; Upton, P.D.; Chambers, W.F. Comparative effects of D-1 amphetamine and 1-phenyl-1-(piperidyl-2′)-1-acetoxy-1-methane (R.P. 8228) in antagonizing barbiturate hypnosis. Arch. Int. Pharmacodyn. Ther., 1963, 145, 553-564.
[PMID: 14067576]
[25]
Yung-Chi, C.; Prusoff, W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22(23), 3099-3108.
[http://dx.doi.org/10.1016/0006-2952(73)90196-2] [PMID: 4202581]
[26]
Zlotos, D.P.; Bender, W.; Holzgrabe, U. Muscarinic receptor agonists and antagonists. Expert Opin. Ther. Pat., 1999, 9(8), 1029-1053.
[http://dx.doi.org/10.1517/13543776.9.8.1029]
[27]
Schenk, S.; Partridge, B. Sensitization to cocaine’s reinforcing effects produced by various cocaine pretreatment regimens in rats. Pharmacol. Biochem. Behav., 2000, 66(4), 765-770.
[http://dx.doi.org/10.1016/S0091-3057(00)00273-2] [PMID: 10973514]
[28]
Schenk, S.; Shippenberg, T.S.; Partridge, B. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl.), 1999, 144(4), 339-346.
[http://dx.doi.org/10.1007/s002130051016] [PMID: 10435406]
[29]
Schenk, S.; Partridge, B.; Shippenberg, T.S. Reinstatement of extinguished drug-taking behavior in rats: Effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl.), 2000, 151(1), 85-90.
[http://dx.doi.org/10.1007/s002130000476] [PMID: 10958121]
[30]
Schenk, S.; Partridge, B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl.), 1999, 147(3), 285-290.
[http://dx.doi.org/10.1007/s002130051169] [PMID: 10639687]
[31]
Morani, A.S.; Kivell, B.; Prisinzano, T.E.; Schenk, S. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol. Biochem. Behav., 2009, 94(2), 244-249.
[http://dx.doi.org/10.1016/j.pbb.2009.09.002] [PMID: 19747933]
[32]
Spangler, R.; Zhou, Y.; Maggos, C.E.; Schlussman, S.D.; Ho, A.; Kreek, M.J. Prodynorphin, proenkephalin and κ opioid receptor mRNA responses to acute “binge” cocaine. Brain Res. Mol. Brain Res., 1997, 44(1), 139-142.
[http://dx.doi.org/10.1016/S0169-328X(96)00249-5] [PMID: 9030708]
[33]
Wee, S.; Koob, G.F. The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl.), 2010, 210(2), 121-135.
[http://dx.doi.org/10.1007/s00213-010-1825-8] [PMID: 20352414]
[34]
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.; Bohn, L.M. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol., 2007, 71(2), 549-557.
[http://dx.doi.org/10.1124/mol.106.028258] [PMID: 17090705]
[35]
Kivell, B.M.; Ewald, A.W.M.; Prisinzano, T.E.; Salvinorin, A. Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv. Pharmacol., 2014, 69, 481-511.
[http://dx.doi.org/10.1016/B978-0-12-420118-7.00012-3] [PMID: 24484985]
[36]
Simonson, B.; Morani, A.S.; Ewald, A.W.M.; Walker, L.; Kumar, N.; Simpson, D.; Miller, J.H.; Prisinzano, T.E.; Kivell, B.M. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br. J. Pharmacol., 2015, 172(2), 515-531.
[http://dx.doi.org/10.1111/bph.12692] [PMID: 24641310]
[37]
Butelman, E.R.; Kreek, M.J. Discriminative stimulus properties of opioid ligands: Progress and future directions. Curr. Top. Behav. Neurosci., 2016, 39, 175-192.
[http://dx.doi.org/10.1007/7854_2016_9] [PMID: 27225498]
[38]
Courvoisier, S. Étude des propriétés stimulantes centrales de l’acétoxy-l-phényl-l(pipéridyl-2′)-l-méthane, threo, levogyre (8228 R. P.). Ann. Med. Psychol. (Paris), 1959, 117, 345.
[39]
Fournier Michel. Contribution to the study of the effects of lidepran. In: Neuro-Psychiatrie Infantile; Faculty of Medicine of Paris: Paris, 1962.
[40]
Dobkin, A.B. Drugs which stimulate affective behavior. 2. Comparison of the analeptic effect of d’amphetamine, bemigride with amiphenazole, methylphenidylacetate, iproniazid (micoren) and RP8228. Anaesthesia, 1960, 15, 146-153.
[http://dx.doi.org/10.1111/j.1365-2044.1960.tb13319.x] [PMID: 13817063]
[41]
Bontronc, C.; Médecine, U. de P. About the psychotonics levophacetoperan and methylphenidate. The Psychoses and in Minor Psychoneurotic States; R. Vezin, 1961.
[42]
Salinger, R.J. Contribution to the experimental study of new psychoactive medications and their therapeutic use in psychiatry: about one of them: 8228 RP or phenyl-1 (piperidyl-2’) 1-acetoxy-methane threolevogyre hydrochloride. 1961.
[43]
Jean-Charles, B.; Trovero, F.; Figadere, B.; Akagah, B.; Konofal, E. [Examination of potential addictive effects of NLS-3, a new compound in development for ADHD]. 4th International Conference on ADHD, 16th-19th OctoberBerlin, Germany, 2016.
[44]
Sivadon, P.; Salinger, R.J.; Quidu, M. Clinical results of the use in psychiatry of a new psychotonic: the 8228 RP (about the first 134 observations). Reports of the Meetings of the Academy of Sciences (Paris), 1960, 760-769.
[45]
Sivadon, P. Salinger René. Ann. Med. Psychol. (Paris), 1962, 120, 824-832.
[PMID: 13913515]
[46]
Chanoit, P-F. Some considerations about the psychotherapeutic use of a new psychotonic. Ann. Med. Psychol. (Paris), 1960, 118, 869-878.
[PMID: 13692358]
[47]
Follin, S.; Chanoit, P-F.; Huchon, J. The use of a new psychotonic: The 8228 RP. In a hospital environment (assessment performed after two years of trials). Reports Meet. Acad. Sci., 1970, 770-776.
[48]
Guyotat, J.; Hochmann, J. The present status of RP-8228 in psychiatric therapeutics. Apropos of 32 recent cases. Lyon Med., 1962, 94, 777-783.
[PMID: 13951512]
[49]
Labaï, C. Clinical results and remarks drawn from the use of iproniazid, RP 82-28 and nialamide in a departmental psychiatric hospital setting; Print South West: Toulouse, 1961.
[50]
Oules, J.; Labaï, C. Therapeutic. Free Subjects: Indications and Use of a New Psychotonic: The 8228 RP. In: Proceedings of the Congress of Psychiatry and Neurology in the French Language Lille, 1960.
[51]
Garde, A. Results obtained with 8.228 R.P. after two years of use of this psychotonic. Lyon Med., 1962, 94, 1549-1555.
[PMID: 13896864]
[52]
Deshaies, G.; Fontaine, C.; Spelz, M.T. Use of a psychotonic in psychiatry. Ann. Med. Psychol. (Paris), 1965, 123, 630-637.
[PMID: 14296669]
[53]
Grimberg, L.; Grimberg-Pivet, S. Psychiatry. Therapeutic. Intervention: Thoughts on the clinical use of 8228 RP. Or levophacetoperane (Lidepran). Proc. Congr. Psychiatry Neurol. French Lang., 1965, 1, p. 812.
[54]
Faure, H.; Faure, M.L. Les Apports Du Nozinan. Neuro-Psychiatrie Infantile (Levomépromazine, 70.44. RP.). Psychological and Sociological Problems in Imbecility; Karger Publishers: Switzerland ; , 1963, pp. 160-164.
[55]
Beaujard, M.; Revol, E. Clinical tests of the activity of RP 8228 (phacetoperane) in an oligophrenic child. Pediatrie, 1960, 15, 310-316.
[PMID: 13797965]
[56]
Guyotat, J.; Beaujard, M.; Guillaumin, J. Psychometric Evaluation of the Effects of a Psychotonic, 8.228R.P. Methodological Considerations. Communication to the Neuro-Psychopharmacological College, Basel, July 4-7, 1960. Neuropharmacology, 1961, 2, 361-370.
[57]
Beaujard, M. Phacetoperane in Mental Retardation of Children. In: International Congress Series; Experta Medica, 1960; p. 100.
[58]
Bellander-Löfvenberg, S.; Osterman, E.; Brattemo, C.E. R P - 8228-Ett nytt psykoanalepticum. Nord. Psykiatr. Tidsskr., 1961, 15(2), 141-147.
[http://dx.doi.org/10.3109/08039486109167941]
[59]
Penteado Bueno, U.; Capp, A.B. Clinical results (consequent to the use of a new psychotonic in oligophrenic and epileptic and oligophrenic minors. Hospital Rio J., 1962, 62, 1003-1017.
[60]
Sivadon, P.; Chanoit, P.-F.; Azoulay, J. First clinical results with a new psychotonic, RP 8228. Méd. Psychol., 1959, 117, 536-541.
[61]
Ban, T.A.; St Laurent, J. The stimulating effect of RP 8228 on inactive psychiatric patients. J. Nutr., 1961, 3, 91-95.
[PMID: 13864565]
[62]
Brattemo, C.E. Experimentalpsykologisk undersökning med ett psykotonicum, RP. - 8228. Nord. Psykiatr. Tidsskr., 1961, 15(2), 147-154.
[http://dx.doi.org/10.3109/08039486109167942]
[63]
Leitch, A.; Seager, C.P. A trial of four anti-depressant drugs. Psychopharmacology (Berl.), 1963, 4(1), 72-77.
[http://dx.doi.org/10.1007/BF00429366] [PMID: 14050414]
[64]
Devic, M.; Revol, M.; Michel, F. [Apropos of the treatment of narcolepsy: trial use of a new psychoactive agent, R.P. 8228]. Lyon Med., 1962, 94, 1557-1562.
[PMID: 13885883]
[65]
Joncev, V.; Stefanova, E. Investigations on levophacetoperan effect upon higher nervous activity and memory. Folia Med. (Plovdiv), 1967, 9(6), 368-372.
[PMID: 4972459]
[66]
Beaujard, M. Phacetoperan in mental retardation in children. , 1963; pp. 165-167.
[67]
Faure, H.; Faure, M.L.; Stoppa, I. The activating effects of phacetoperan in childhood neuropsychiatry. J. Child Neuropediatrics Childhood Mental Hygiene, 1962, 10, 7-8.
[68]
Cutler, M.; Little, J.; Strauss, A. The effect of benzedrine on mentally deficient children. Am. J. Ment. Defic., 1940, 45, 59-65.
[69]
Morris, J.V.; Macgillivray, R.C.; Mathieson, C.M. The results of the experimental administration of amphetamine sulphate in oligophrenia. J. Ment. Sci., 1955, 101(422), 131-140.
[http://dx.doi.org/10.1192/bjp.101.422.131] [PMID: 14368214]
[70]
Raymond, F.; Janet, P. Review of les obsessions et la psychasthénie. Am. J. Psychol.,1903, 14(2), 262-264.
[http://dx.doi.org/10.2307/1412725]
[71]
Pitman, R.K. Janet’sObsessions and psychasthenia: A synopsis. Psychiatr. Q., 1984, 56(4), 291-314.
[http://dx.doi.org/10.1007/BF01064475] [PMID: 6399751]
[72]
Hubin, P.; Servais, J. study of the subjective effects of amphtamine in humans according to personality. Psychopharmacology (Berl.), 1968, 12(3), 239-249.
[http://dx.doi.org/10.1007/BF00403778]
[73]
Sutter, J.M.; Delpretti, G.M. Levophacetoperane (lidepran) in psychiatric therapeutics. Sud Med. Chir., 1962, 998-1005.
[74]
Fluyau, D.; Mitra, P.; Lorthe, K. Antipsychotics for amphetamine psychosis. A systematic review. Front. Psychiatry, 2019, 10, 740.
[http://dx.doi.org/10.3389/fpsyt.2019.00740] [PMID: 31681046]
[75]
Doyle, J.B.; Daniels, L.E. Narcolepsy; Results of treatment with ephedrine sulphate. J. Am. Med. Assoc., 1932, 98(7), 542-545.
[http://dx.doi.org/10.1001/jama.1932.02730330024006]
[76]
Yoss, R.E.; Daly, D. Treatment of narcolepsy with Ritalin. Neurology, 1959, 9(3), 171-173.
[http://dx.doi.org/10.1212/WNL.9.3.171] [PMID: 13632876]
[77]
Janota, O. Treatment of Narcolepsy With Ephedrine. Proceedings of the Proceedings of the work of the Neuro-Psychiatric Section of the 14th Congress of Polish Physicians and Naturalists, Poznan, 1933.
[78]
Mondenard, J. Doping: Piperidines: Lidépran, Mératran, Ritalin. Odds and ends without great effects. Médecine du sport, 1991, 65, 00145-00148.
[79]
Delbeke, F.T.; Debackere, M. Isolation and detection of methylphenidate, phacetoperane and some other sympatomimetic central nervous stimulants with special reference to doping. J. Chromatogr. A, 1975, 106(2), 412-417.
[http://dx.doi.org/10.1016/S0021-9673(00)93853-6] [PMID: 239015]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy